<DOC>
	<DOC>NCT01764776</DOC>
	<brief_summary>This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects with impaired hepatic function and healthy subjects with normal hepatic function.</brief_summary>
	<brief_title>Effect of Hepatic Impairment on LDE225..</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria (all groups): Male and sterile or postmenopausal female age ≥18 to ≤70 years old. Normal Vital signs Inclusion (group mild, moderate and severe hepatic impairment): Subjects with confirmed cirrhosis Exclusion (all groups): Woman of childbearing potential and pregnant or lactating females or male not using condom Risk factors for torsades de pointes Clinically significant cardiovascular disease severe or uncontrolled medical conditions Smokers consuming greater than 10 cigarettes or equivalent nicotine containing products per day. Use of investigational drugs (i.e. participation in any clinical investigation) Exclusion for moderate, mild and severe groups: Symptoms or history of encephalopathy Clinical evidence of severe ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LDE225</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>Postmenopausal women</keyword>
	<keyword>normal hepatic function</keyword>
	<keyword>mild hepatic impairment</keyword>
	<keyword>moderate hepatic impairment</keyword>
	<keyword>severe hepatic impairment</keyword>
</DOC>